Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure: rationale, design and baseline characteristics of a proof-of-concept, randomised, precision-medicine, prevention trial. The Heart OMics in AGing (HOMAGE) trial

Pierpaolo Pellicori*, Joao Pedro Ferreira, Beatrice Mariottoni, Hans-Peter Brunner-La Rocca, Fozia Z. Ahmed, Job Verdonschot, Tim Collier, Joe J. Cuthbert, Johannes Petutschnigg, Blerim Mujaj, Nicolas Girerd, Arantxa Gonzalez, Andrew L. Clark, Franco Cosmi, Jan A. Staessen, Stephane Heymans, Roberto Latini, Patrick Rossignol, Faiez Zannad, John G. F. Cleland

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)1711-1723
Number of pages13
JournalEuropean journal of heart failure
Volume22
Issue number9
DOIs
Publication statusPublished - Sep 2020

Keywords

  • HOMAGE
  • Spironolactone
  • Fibrosis
  • Biomarkers
  • Study design
  • PRESERVED EJECTION FRACTION
  • EXTRACELLULAR-MATRIX TURNOVER
  • BRAIN NATRIURETIC PEPTIDE
  • DOUBLE-BLIND
  • ALDOSTERONE ANTAGONISM
  • DIASTOLIC DYSFUNCTION
  • MYOCARDIAL-INFARCTION
  • COLLAGEN TURNOVER
  • NT-PROBNP
  • BIOMARKERS

Cite this